TYRP1 and early-onset autosomal dominant Alzheimer disease: The broad-spectrum cathepsin inhibitor E64d and the specific CatB inhibitor CA-074Me were both proved capable of reducing brain β-amyloid peptides and improving memory in the murine Alzheimer’s disease model[42].